ALC vs WST
Alcon Inc. and West Pharmaceutical Services, both Healthcare
Alcon Inc. is the larger company at $33B against $23B. On trailing earnings WST is the cheaper of the two at a P/E of 46.9 against 48.2, a gap that is only a bargain if the two are growing at similar rates. Over the past year WST returned +44% against -17% for ALC. The RyuScore puts WST ahead, 62 against 51 out of 100.
| Figure | ALC | WST |
|---|---|---|
| Last close | $64.11 | $366 |
| Market cap | $33B | $23B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 48.2 | 46.9 |
| Dividend yield | n/a | 0.2% |
| 1-year return | -17% | +44% |
| 5-year return | -25% | -16% |
| RyuScoresector-relative, 1–10 | 51/100 | 62/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Alcon Inc.
Revenue of $5.3B in H2 2025, net income $454M.
West Pharmaceutical Services
Revenue of $872M in Q2 2026, net income $154M. Its largest reported line is Proprietary Products, 83% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.